|
1
|
|
|
2
|
- Statewide resource for disease gene identification and genetic data
analysis.
- ACoRN will initially seek to identify genes that cause or contribute to
cardiovascular disease.
- Funded by NIH WV-BRIN grant.
|
|
3
|
|
|
4
|
- Disease are caused by one or more genes (mutations) and by environmental
factors
- The disease is familial but no Mendelian pattern of inheritance can be
detected.
- Genes that predispose or raise risk are called susceptibility genes
- Examples: Atherosclerosis, Alzheimer’s, type 2 diabetes, autism,
hypertension, obesity
|
|
5
|
- Genetic heterogeneity: more than
one susceptibility gene acting alone or in combination
- Phenotype can vary continuously (quantitative traits)
- Some have high incidence in a population and called Common Complex
diseases
|
|
6
|
- WV ranks 49th in the prevalence of heart disease (ReliaStar
Financial Corporation)
- WV ranks 50th in risk of heart disease based on three
factors: obesity, hypertension and sedentary lifestyle. (ReliaStar)
|
|
7
|
- IDENTIFY FAMILIES WITH INHERITED CARDIOVASCULAR DISEASES (MONOGENIC AND
MULTIFACTORIAL)
- FIND DISEASE SUSCEPTIBILITY GENES THROUGH GENE MAPPING OR FUNCTIONAL
GENOMIC APPROACHES
- GENE IDENTITY WILL HELP DETERMINE MECHANISM OF PATHOGENESIS
|
|
8
|
- CLINICIANS - IDENTIFY CV
AFFECTEDS
- RURAL CLINICS (5 PLANNED)
- GENETIC COUNSELORS – PATIENT COUNSELING
- DATABASE MANAGER- DATA COLLECTION AND SHARING
- CARDIOVASCULAR RESEARCHERS AND GENETIC ANALYSTS- USE DATA TO IDENTIFY
DISEASE GENES AND DEVELOP MODELS OF DISEASE DEVELOPMENT
|
|
9
|
- IDENTIFICATION OF SUSCEPTIBILITY GENES WILL LEAD TO:
- EARLY DETECTION OF DISEASE
- BETTER UNDERSTANDING OF PATHOGENESIS
- IMPROVED/EARLIER TREATMENT OF CV DISEASE
|
|
10
|
- Identification of disease genes and pathways can lead to development of
- (1) new targets for
pharmacological agents
- (2) methods for reliable
detection of mutation genotype
- (3) programs which tailor
behavior modification to the underlying defect
|
|
11
|
- Early onset form caused by defects in either APP, presenilin1 or
presenilin 2;
- These account for the majority of early onset cases, but only for 5% of
all cases
- Late onset seems to related to allelic status at APOE where e4 raised
risk and decreases age of onset
|